To identify the therapeutic vulnerabilities of CRC cells, we engineered a bi‐allelic APC mutated CRC (APCdef) cell line to re‐express full‐length APC (APCres) in a doxycycline‐dependent manner [5]. The gene discussed is APC; the disease is colorectal carcinoma.